Magle Chemoswed Holding (MAGLE) Fair Value & Analysis
Healthcare · SE · Market cap 20.9M SEK
Fair value as of: Jul 13, 2026
From 1 valuation models · updated yesterday
Fair value updated Jul 13, 2026 — revised from kr 27.31 to kr 1.30 (−95.3%) since Jun 24, 2026. Share price −23.4% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 1.00 – kr 26.60 · fair‑value band kr 0.9677 – kr 1.94 · the kr 1.28 price screens below the kr 1.30 fair value. As of Jul 13, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Magle Chemoswed Holding (MAGLE) currently trades at kr 1.28, while our model-based Fair Value estimate is kr 1.30 — implying the stock looks roughly 1.3% fairly valued today. We read business quality at 19/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Magle Chemoswed Holding generated revenue of 288M SEK at a net margin of -55.6%. Revenue declined 14.5% year over year. It earns a return on equity of -33.4%. Net debt stands at 333M SEK. Fundamentals as of Jul 13, 2026
Our scenario range runs from kr 0.9677 (bear case) to kr 1.94 (bull case); at kr 1.28, the current price sits within that range. For context, the median of 10 Healthcare peers we cover trades at -32% fair-value upside — at 1%, MAGLE screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 13, 2026. TTM = trailing twelve months.
About the company
Magle Chemoswed Holding AB (publ), together with its subsidiaries, engages in research and development of pharmaceutical and medical device products in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; and benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson's disease. The company also offers EmboCept S, a microsphere-based medical device used in vascular occlusion of liver and lung tumors; SmartGel, a non-allergenic hydrogel based on the company's microsphere technology; and SmartPAN, a medical device for the detection of pancreatic fluid leakage during open or minimally invasive surgical procedures. In addition, it is developing EmboCept M for the treatment of benign prostatic hyperplasia; EmboCept L for the treatment of uterine fibroids; SmartGel II, an advanced wound …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Magle Chemoswed Holding reported revenue of kr 283M in FY2025 versus kr 132M in FY2021, a compound +21.0%/yr. Reported net income was −kr 160M in FY2025.
Is MAGLE fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$562.61 | R$385.38 | -32% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$52.30 | R$9.67 | -82% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
| CSL Limited CSL | A$116.32 | A$126.60 | +9% |
| Celltrion, Inc 068270 | 168,500 KRW | 76,943 KRW | -54% |
| BioNTech SE B1NT34 | R$29.19 | R$21.38 | -27% |
| Moderna, Inc M1RN34 | R$11.81 | R$3.77 | -68% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Magle Chemoswed Holding (MAGLE) undervalued?
What is the fair value of MAGLE?
What is the quality score of MAGLE?
What is the revenue of Magle Chemoswed Holding (MAGLE)?
What is the net profit margin of MAGLE?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full Magle Chemoswed Holding analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.